Emergent Biosolutions Inc. (EBS) Given Average Rating of “Buy” by Brokerages
Emergent Biosolutions Inc. (NYSE:EBS) has earned an average recommendation of “Buy” from the six research firms that are currently covering the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $37.50.
EBS has been the topic of a number of research analyst reports. Singular Research cut their target price on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, June 28th. Wells Fargo & Co. reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Wednesday, June 22nd. Cowen and Company reissued a “hold” rating and issued a $33.00 target price on shares of Emergent Biosolutions in a research report on Sunday, August 7th. Zacks Investment Research raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Finally, JPMorgan Chase & Co. cut their target price on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research report on Friday, August 5th.
Shares of Emergent Biosolutions (NYSE:EBS) traded down 1.74% during mid-day trading on Thursday, hitting $30.46. The stock had a trading volume of 219,325 shares. The firm has a market cap of $1.23 billion, a PE ratio of 21.79 and a beta of 1.12. Emergent Biosolutions has a 12 month low of $26.12 and a 12 month high of $44.38. The stock’s 50-day moving average is $28.61 and its 200 day moving average is $34.02.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The firm had revenue of $101.49 million for the quarter, compared to analysts’ expectations of $111.20 million. Emergent Biosolutions had a net margin of 11.61% and a return on equity of 11.93%. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.36 EPS. Equities research analysts predict that Emergent Biosolutions will post $1.03 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of the company. State Street Corp increased its position in shares of Emergent Biosolutions by 23.3% in the first quarter. State Street Corp now owns 1,099,602 shares of the biopharmaceutical company’s stock worth $39,969,000 after buying an additional 208,084 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Emergent Biosolutions by 16.9% in the first quarter. Renaissance Technologies LLC now owns 1,112,811 shares of the biopharmaceutical company’s stock worth $40,451,000 after buying an additional 161,200 shares during the last quarter. Aperio Group LLC increased its position in shares of Emergent Biosolutions by 25.7% in the first quarter. Aperio Group LLC now owns 10,542 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 2,154 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Emergent Biosolutions by 2.2% in the second quarter. Fisher Asset Management LLC now owns 467,770 shares of the biopharmaceutical company’s stock worth $14,253,000 after buying an additional 10,028 shares during the last quarter. Finally, HBK Investments L P purchased a new position in shares of Emergent Biosolutions during the first quarter worth approximately $947,000. Hedge funds and other institutional investors own 89.93% of the company’s stock.
About Emergent Biosolutions
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.